Rapid innovations in prostate cancer diagnosis and treatment have led to the adoption of innovative trial designs.
The Imperial Prostate 3-PROState Pathway Embedded Comparative Trial (IP3-PROSPECT) aims to explore the feasibility and acceptability of a cohort multiple randomised controlled trial (cmRCT) design within the prostate cancer pathway.
